

## DAFTAR PUSTAKA

- Abdel Misih, S. R. Z. and Bloomston, M. 2010. *Liver Anatomy*. **Surgical Clinics of North America**. 90(4), 643–653. <https://doi.org/10.1016/j.suc.2010.04.017>
- Abdul Kadir, N. A. A., Rahmat, A. dan Jaafar, H. Z. E. 2015. *Protective effects of tamarillo (cyphomandra betacea) extract against high fat diet induced obesity in sprague-dawley rats*. **Journal of Obesity**. <https://doi.org/10.1155/2015/846041>
- Albert, L. 2000. *Biochemistry Fundament, Carbohydrat, Protein, Lipid Metabolism*. The Johns Hopkins University.
- Alkhoury N, Gornicka A, Berk MP, Thapaliya S, Dixon LJ, Kashyap S, Schauer PR, and Feldstein AE. 2010. *Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis*. **J Biol Chem**. 285:3428–3438.
- Allen, E. S. 2002. *The Liver: Anatomy, Physiology, Disease and Treatment*. **Human Anatomy & Physiology**. pp. 3–11.
- Bellentani, S. and Marino, M. 2009. *Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)*. **Annals of Hepatology**. 8(SUPPL. 1), S4–S8. [https://doi.org/10.1016/s1665-2681\(19\)31820-4](https://doi.org/10.1016/s1665-2681(19)31820-4)
- Bellentani, S., Scaglioni, F., Marino, M., and Bedogni, G. 2010. *Epidemiology of non-alcoholic fatty liver disease*. **Digestive Diseases**. 28(1), 155–161. <https://doi.org/10.1159/000282080>
- Bjermo H, Iggman D, Kullberg J, Dahlman I, Johansson L, Persson L, Berglund J, Pulkki K, Basu S, Uusitupa M, Rudling M, Arner P, Cederholm T, Ahlstrom H, and Riserus U. 2012. *Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial*. **Am J Clin Nutr** . 95:1003–1012.

- Brunt, E. M., Janney, C. G., Bisceglie, A. M. Di, Neuschwander-tetri, B. A. and Bacon, B. R. 1999. *Nonalcoholic steatohepatitis - a proposal for grading and staging*. 94(9).
- Brunt EM, Kleiner DE, Wilson LA, Belt P, and Neuschwander. 2011. *The NAS and the histopathologic diagnosis of NASH: distinct clinicopathologic meanings*. **Hepatology**. Tetri BA : NASH Clinical Research Network. 53:810-820.
- Chinnadurai K, Kanwal HK, Tyagi AK, Stanton C, and Ross P. 2013. *High conjugated linoleic acid enriched ghee (clarified butter) increases the antioxidant and antiatherogenic potency in female Wistar rats*. **Lipids Health Dis**. 12:121
- Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A, and Network NCR. 2008. *Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with nonalcoholic fatty liver disease*. **Journal of hepatology**. 48:829–834.
- Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, and Parks EJ. 2005. *Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease*. **J Clin Invest** . 115:1343–1351.
- Du, Z., Yang, Y., Hu, Y., Sun, Y., Zhang, S., Peng, W., ... Kong, W. 2012. *A long-term high-fat diet increases oxidative stress, mitochondrial damage and apoptosis in the inner ear of d-galactose-induced aging rats*. **Hearing Research**. 287(1–2), 15–24. <https://doi.org/10.1016/j.heares.2012.04.012>
- Duwaerts, C. C. and Maher, J. J. 2019. *Macronutrients and the Adipose-Liver Axis in Obesity and Fatty Liver*. **Cmgh**. 7(4), 749–761. <https://doi.org/10.1016/j.jcmgh.2019.02.001>

- Duwaerts CC, Amin AM, Siao K, Her C, Fitch M, Beysen C, Turner SM, Goodsell A, Baron JL, Grenert JP, Cho SJ, and Maher JJ. 2017. *Specific macronutrients exert unique influences on the adipose-liver axis to promote hepatic steatosis in mice.* **Cell Mol Gastroenterol Hepatol.** 4:223–236.
- Dyson, J. K., Anstee, Q. M. and McPherson, S. 2014. *Non-alcoholic fatty liver disease: A practical approach to treatment.* **Frontline Gastroenterology.** 5(4), 277–286. <https://doi.org/10.1136/flgastro-2013-100404>
- Esler, W. P. and Bence, K. K. 2019. *Metabolic Targets in Nonalcoholic Fatty Liver Disease.* **Cmgh.** 8(2), 247–267. <https://doi.org/10.1016/j.jcmgh.2019.04.007>
- Fan, J.G. and Cao, H.X. 2013. *Role of Diet and Nutritional Management in Non-Alcoholic Fatty Liver Disease.* **J. Gastroenterol. Hepatol.** 28, 81–87.
- Ferramosca, A., Di Giacomo, M., and Zara, V. 2017. *Antioxidant dietary approach in treatment of fatty liver: New insights and updates.* **World Journal of Gastroenterology.** 23(23), 4146–4157. <https://doi.org/10.3748/wjg.v23.i23.4146>
- Fielding B. 2013. *Tracing the fate of dietary fatty acids: metabolic studies of postprandial lipaemia in human subjects.* **Proc Nutr Soc.** 70:342–350.
- Finucane OM, Lyons CL, Murphy AM, Reynolds CM, Klinger R, Healy NP, Cooke AA, Coll RC, McAllan L, Nilaweera KN, O'Reilly ME, Tierney AC, Morine MJ, Alcalá-Díaz JF, López-Miranda J, O'Connor DP, O'Neill LA, McGillicuddy FC, Roche HM. 2015. *Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1 $\beta$  secretion and insulin resistance despite obesity.* **Diabetes.** 64:2116–2128.

- Frayn KN., and Kingman SM. 1995. *Dietary sugars and lipid metabolism in humans*. **Am J Clin Nutr** . 62:250S–261S.
- Gaggini, M., Morelli, M., Buzzigoli, E., DeFronzo, R. A., Bugianesi, E., and Gastaldelli, A. 2013. *Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease*. 1544–1560. <https://doi.org/10.3390/nu5051544>
- Gentile CL, Weir TL, Cox-York KA, Wei Y, Wang D, Reese L, Moran G, Estrada A, Mulligan C, Pagliassotti MJ, and Foster MT. 2015. *The role of visceral and subcutaneous adipose tissue fatty acid composition in liver pathophysiology associated with NAFLD*. **Adipocyte**. 4:101–112.
- Hariri, N. and Thibault, L. 2010. *High-Fat Diet-Induced Obesity in Animal Models*. **Nutr. Res. Rev**, 23, 270–299.
- Hermanto, S., Muawanah, A., dan Harahap, R. 2008. *Profil dan Karakteristik Lemak Hewani (Ayam, Sapi dan Babi) Hasil Analisa FTIR dan GCMS*. **Jurnal Kimia VALENSI**. 1(3), 102–109. <https://doi.org/10.15408/jkv.v1i3.219>
- Hoefel AL, Hansen F, Rosa PD, Assis AM, Silveira SL, Denardin CC, Pettenuzzo L, Augusti PR, Somacal S, Emanuelli T, Perry ML, Wannmacher CM. 2011. *The effects of hypercaloric diets on glucose homeostasis in the rat: influence of saturated and monounsaturated dietary lipids*. **Cell Biochem Funct** . 29:569–576.
- Hübscher, S. G. 2006. *Histological assessment of non-alcoholic fatty liver disease*. **Histopathology**. 49(5), pp. 450–465. doi: 10.1111/j.1365-2559.2006.02416.x.
- Hwang, J. 2009. *Diets with corn oil and/or low protein increase acute acetaminophen hepatotoxicity compared to diets with beef tallow in a*

- rat model. Nutrition Research and Practice.* 3(2), 95.  
<https://doi.org/10.4162/nrp.2009.3.2.95>
- Innes, J. K. and Calder, P. C. 2018. *Omega-6 fatty acids and inflammation. Prostaglandins Leukotrienes and Essential Fatty Acids.* 41–48.  
<https://doi.org/10.1016/j.plefa.2018.03.004>
- Johnson S. and Saikia N. 2009. *Fatty acid profile of edible oils and fats in India. CSE:40-42.*
- Juárez-Hernández, E., Chávez-Tapia, N.C., Uribe, M., Barbero-Becerra, V.J. 2015. *Role of Bioactive Fatty Acids in Nonalcoholic Fatty Liver Disease. Nutr. J.* 15, 72.
- Kakimoto, P.A. and Kowaltowski, A.J. 2016. *Effects of high fat diets on rodent liver bioenergetics and oxidative imbalance. Redox Biol.* 8, 216–225.
- Kalupahana NS, Claycombe K, Newman SJ, Stewart T, Siriwardhana N, Matthan N, Lichtenstein AH, MoustaidMoussa N. 2010. *Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. J Nutr.* 140:1915–1922
- Kanuri, G. and Bergheim, I. 2013. *In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD). Int. J. Mol. Sci.* 14, 11963–11980
- Ke, M. and Raju, S. 2014. *Comparative histology of human and cow, goat and sheep liver. Journal of Surgical Academia.* 4(1), 10–13.
- Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., and Sanyal, A. J. 2005. *Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology.* 41(6), 1313–1321. <https://doi.org/10.1002/hep.20701>

- Koo, S. H. 2013. *Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis*. **Clinical and Molecular Hepatology**. 19(3), 210–215. <https://doi.org/10.3350/cmh.2013.19.3.210>
- Lambert, J. E., Ramos-Roman, M. A., Browning, J. D., and Parks, E. J. 2014. *Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease*. **Gastroenterology**. 146(3), 726–735. <https://doi.org/10.1053/j.gastro.2013.11.049>
- Lau, J.K.C., Zhang, X., and Yu, J. 2017. *Animal Models of Non-Alcoholic Fatty Liver Disease: Current Perspectives and Recent Advances*. **J. Pathol.** 241, 36–44.
- Lee YS, Kim JW, Osborne O, Oh DY, Sasik R, Schenk S, Chen A, Chung H, Murphy A, Watkins SM, Quehenberger O, Johnson RS, Olefsky JM. 2014. *Increased adipocyte O<sub>2</sub> consumption triggers HIF-1 $\alpha$ , causing inflammation and insulin resistance in obesity*. **Cell**. 157:1339-1352
- Lefkowitz, J. H. 2011. *Chapter 1 Anatomy and Function. Sherlock's Diseases of the Liver and Biliary System*. 12th Edition. 1–19.
- Lefkowitz JH, Haythe JH, Regent N. 2002. *Kupffer cell aggregation and perivenular distribution in steatohepatitis*. **Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc.** 15:699–704.
- Levene, A. P. and Goldin, R. D. 2012. *The epidemiology, pathogenesis and histopathology of fatty liver disease*. **Histopathology**. 61(2), 141–152. <https://doi.org/10.1111/j.1365-2559.2011.04145.x>
- Matsumoto, M., Hada, N., Sakamaki, Y., Uno, A., Shiga, T., Tanaka, C., Sudoh, M. 2013. *An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis*. **International Journal of Experimental Pathology**. 94(2), 93–103. <https://doi.org/10.1111/iep.12008>

- Malarkey, D. E., Johnson, K., Ryan, L., Boorman, G., & Maronpot, R. R. 2005. *New Insights into Functional Aspects of Liver Morphology. Toxicologic Pathology*, 33(1), 27–34. <https://doi.org/10.1080/01926230590881826>
- Murray. K. 2002. *Harper Biochemistry, twenty fifth edition. Mc Graw Hill Companie: New York.*
- Ozougwu, J. C. and Eyo, J. E. 2014 'Hepatoprotective effects of *Allium cepa* (onion) extracts against paracetamol-induced liver damage in rats'. *African Journal of Biotechnology*. 13(26), pp. 2679–2688. doi: 10.5897/AJB2014.13815.
- Paderi A.Z. 2007. *Kajian Perubahan Jaringan Uji Khasiat Buah Merah (Pandanus conoideus) sebagai Bahan Penghambat Kerusakan Hati. Fakultas Kedokteran Hewan, Institut Pertanian Bogor.*
- Paradies, G., Paradies, V., Ruggiero, F. M., and Petrosillo, G. 2014. *Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World Journal of Gastroenterology*. 20(39), 14205–14218. <https://doi.org/10.3748/wjg.v20.i39.14205>
- Rolo, A. P., Teodoro, J. S., and Palmeira, C. M. 2012. *Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biology and Medicine*. 52(1), 59–69. <https://doi.org/10.1016/j.freeradbiomed.2011.10.003>
- Rosqvist F, Iggman D, Kullberg J, Cedernaes J, Johansson HE, Larsson A, Johansson L, Ahlstrom H, Arner P, Dahlman I, Riserus U. 2014. *Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes* . 63:2356–2368.
- Sampath H, Miyazaki M, Dobrzyn A, Ntambi JM. 2007. *Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat. J Biol Chem* . 282:2483–2493.

- Sanyal, A., Friedman, S., McCullough, A., Dimick, L., and Running. 2015. *Challenges and Opportunities in Drug and Biomarker*. **Hepatology**.
- Shilpa, J., Mohan, V. 2018. *Ketogenic Diets: Boon or bane?*. **Indian J Med Res**. 148(3): 251–253.
- Song Z, Xiaoli AM, Yang F. 2018. *Regulation and metabolic significance of de novo lipogenesis in adipose tissues*. *Nutrients*. 10:1383.
- Schwenger, K. J. P. and Allard, J. P. 2014. *Clinical approaches to non-alcoholic fatty liver disease*. **World Journal of Gastroenterology**. 20(7), 1712–1723. <https://doi.org/10.3748/wjg.v20.i7.1712>
- Shukla DJ, Vyas HA, Vyas MK, Ashok BK, and Ravishankar B. 2012. *A comparative study on chronic administration of Go Ghrita and Avika Ghrita in albino rats* *Ayu*. 33(3):435-40.
- Sudiono, J. B., Kurniadhi, Hendrawan, A., dan Djinantoro, B. 2003. *Ilmu Patologi*. Penerbit EGC. Jakarta.
- Trayhurn, P. 2013. *Hypoxia and adipose tissue function and dysfunction in obesity*. **Physiological Reviews**. 93(1), 1–21. <https://doi.org/10.1152/physrev.00017.2012>
- Tveden-Nyborg, P., Birck, M. M., Ipsen, D. H., Thiessen, T., Feldmann, L. de B., Lindblad, M. M., ... Lykkesfeldt, J. 2016. *Diet-induced dyslipidemia leads to nonalcoholic fatty liver disease and oxidative stress in guinea pigs*. **Translational Research**. 168, 146–160. <https://doi.org/10.1016/j.trsl.2015.10.001>
- Younossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., and Hunt, S. 2015. *Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009*. **Hepatology**. 62(6), 1723–1730. <https://doi.org/10.1002/hep.28123>



- Foster, R., Williamson, C. S., & Lunn, J. 2009. *Culinary oils and their health effects*. **Nutrition Bulletin**. 34(1), 4–47. <https://doi.org/10.1111/j.1467-3010.2008.01738.x>
- Otaegui-Arrazola, A., Menéndez-Carreño, M., Ansorena, D., and Astiasarán, I. 2010. Oxysterols: A world to explore. **Food and Chemical Toxicology**. 48(12), 3289–3303. <https://doi.org/10.1016/j.fct.2010.09.023>
- Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Sanyal, A. J. 2012. *The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases*. American College of Gastroenterology, and the American Gastroenterological Association. **Hepatology**. 55(6), 2005–2023. <https://doi.org/10.1002/hep.25762>
- Ronis, M. J. J., Baumgardner, J. N., Sharma, N., Vantrease, J., Ferguson, M., Tong, Y., Badger, T. M. 2013. *Medium chain triglycerides dose-dependently prevent liver pathology in a rat model of non-alcoholic fatty liver disease*. **Experimental Biology and Medicine**. 238(2), 151–162. <https://doi.org/10.1258/ebm.2012.012303>
- Wree A, Schlattjan M, Bechmann LP, Claudel T, Sowa JP, Stojakovic T, Scharnagl H, Kofeler H, Baba HA, Gerken G, Feldstein AE, Trauner M, Canbay A. 2014. *Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients*. **Metabolism**. 63:1542–1552.